-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 SDQ7+N+8NTavwh8KPj4sovtLuKQRT9gZR/v/d3XDnmM6xHptRVu+yLPZTy+AjqJU
 +thAlY/PdZNGHtHjWf239A==

<SEC-DOCUMENT>0000950144-08-007693.txt : 20081020
<SEC-HEADER>0000950144-08-007693.hdr.sgml : 20081020
<ACCEPTANCE-DATETIME>20081020161031
ACCESSION NUMBER:		0000950144-08-007693
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20081020
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20081020
DATE AS OF CHANGE:		20081020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		081131554

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g16151e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>FORM 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>








<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>
Date of report (Date of earliest event reported): October&nbsp;20, 2008</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
<B>(Exact name of registrant as specified in Charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware<BR>
(State or other jurisdiction of <BR>
incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091<BR>
(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038<BR>
(IRS Employee Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<B>1256 Briarcliff Road N.E.<BR>

Emtech Bio Suite&nbsp;500<BR>

Atlanta, Georgia 30306<BR>

(Address of Principal Executive Offices)</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<B>(404)&nbsp;727-0971<BR>

(Issuer Telephone number)</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Registrant under any of the following provisions (see General
Instruction A.2 below).</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4<SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> under the Exchange Act (17 CFR
240.13(e)-4(c))
</TD>
</TR>
</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<!--TOC-->
<!--/TOC-->





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time
to time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>
<!-- link1 "Item&nbsp;8.01 Other Events" -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;8.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Other Events</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On October&nbsp;20, 2008 we issued a press release announcing the shipment of both the DNA and MVA
components of our AIDS vaccine to the HIV Vaccine Trials Network (HVTN)&nbsp;pharmacy, for use in the
upcoming Phase 2a human clinical trial. A copy of the press release is attached to this Current
Report.</DIV>

<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits" -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99.1 &nbsp;&nbsp;Press Release</DIV>




<P align="right" style="font-size: 10pt"><!-- Folio -->2 of 3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: October&nbsp;20, 2008
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="right" style="font-size: 10pt"><!-- Folio -->3 of 3<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>g16151exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g16151g1615100.gif" alt="(GEOVAX LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">Contact:<BR>
Financial Relations Board<BR>
Melanie Nimrodi<BR>
312.546.3508 or <u>mnimrodi@frbir.com</u><BR>
At The Company<BR>
Bob McNally<BR>
404.727.0971 or <u>bmcnally@geovax.com</u>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">FOR IMMEDIATE RELEASE
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>GeoVax&#146;s DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in
the Upcoming Phase 2a Trial</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ATLANTA  &#151;  October&nbsp;20, 2008  &#151;  GeoVax Labs, Inc. (OTC BB: GOVX), </B>an Atlanta based biotechnology
company, developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and
other infectious agents, announced today it has shipped both DNA and MVA components of its AIDS
vaccine to the HIV Vaccine Trials Network (HVTN)&nbsp;pharmacy, for use in the upcoming Phase 2a human
clinical trial. This Phase 2a study will involve 150 vaccinees and 75 placebo (control)
participants. These trials serve as a major milestone, as Phase 2a trials are the most advanced
trials to-date for GeoVax.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dr.&nbsp;Robert McNally, President and CEO of GeoVax Labs Inc., commented, &#147;The shipment of the vaccine
to the HIV Vaccine Trials Network is a significant step in preparation for the largest clinical
trial yet to be undertaken by GeoVax. Multiple completed Phase 1 safety trials refined the dose and
vaccine delivery intervals to optimize the immune responses considered desirable to achieve
protection against the HIV-1 virus causing AIDS.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Further, a Biological Master File has been submitted to the Food and Drug Administration (FDA)&nbsp;for
review of the manufacturing data for the product shipped to HVTN for use in the Phase 2a trial. The
FDA completes its review within four weeks. Upon FDA clearance, HVTN&#146;s pharmacy will release
GeoVax&#146;s DNA and MVA vaccines for its planned Phase 2a trial commencement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease
(AIDS)&nbsp;caused by the virus known as HIV-1 by vaccinating individuals prior to virus infection. The
vaccine regimen employs a two component &#147;prime-boost strategy.&#148; Trial participants are first
administered GeoVax HIV-1 DNA vaccine which &#147;primes&#148; the immune system followed by the second
vaccine, GeoVax&#146;s HIV-1 MVA (Modified Vaccinia Virus) boost. Both vaccines express the 3 major
proteins of the AIDS virus. These proteins mimic more than 50% of the components of the AIDS virus
(HIV-1) but cannot cause AIDS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>About GeoVax Labs, Inc. </B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other
infectious agents. GeoVax&#146;s AIDS vaccine technology is the subject of 20 issued or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="g16151g1615100.gif" alt="(GEOVAX LOGO)">
</DIV>




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to
prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the
person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics (treatment
of people already infected with AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected
individuals are in the planning stage.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax&#146;s core AIDS vaccine technologies were developed through a collaboration of colleagues at
Emory University&#146;s Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease
Control and Prevention (CDC)&nbsp;and the GeoVax team.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine
Trials Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded through a cooperative
agreement with the National Institutes of Health &#091;NIH), is the largest worldwide clinical trials
program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by <B>NIAID</B>, which provided
additional support to GeoVax AIDS vaccine development program with a $15&nbsp;million IPCAVD grant
awarded in late 2007. <u>www.geovax.com</u>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe Harbor Statement: All statements in this news release, not statements of historical fact, are
forward-looking statements. These statements are based on expectations and assumptions on the date
of this press release and are subject to numerous risks and uncertainties which could cause actual
results to differ materially from those described in the forward-looking statements. Risks and
uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these
vaccines with the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be safe for
human use, GeoVax&#146;s vaccines will effectively prevent AIDS in humans, vaccines will receive
regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to
complete vaccine development, there is development of competitive products that may be more
effective or easier to use than GeoVax&#146;s products, and other factors over which GeoVax has no
control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. Certain matters discussed in this news release are forward-looking statements
involving certain risks and uncertainties including, without limitation, risks detailed in the
Company&#146;s Securities and Exchange Commission filings and reports.</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>###</I>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g16151g1615100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16151g1615100.gif
M1TE&.#EAX``H`.8``*7)V?[^^_[]_<C:XG.BN;+,UX.GNT5XEL34W>3M\5F)
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M;REQ??S\\TV0L(ZMOI>[QTZ-J5*.KUV`G+[/UAU57^_O\/___R'Y!```````
M+`````#@`"@```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
M,QD9;:"FIZBIJHPB$@T16*NRL[2UDP1?7A"VO+V^AE@+-`P0$"(#!5!0!3(3
M,F//(04%%0,#1!`J"4$9`H0T41@`O^3EG5@J3@,5)S)W!"9>-QPM]0T--3T-
M9"1B2RT6+.3`L(8#!PL<RM0``F2AF!Q>3$1(AN*("A$)F)C;R)&1`!4#D%SP
MX>4'AR4O$&)`L>3(BQYI0*3A00$&#!\L"%R($>,#3Y\&+A#P$`$&!1X'7DCA
M@$%,`1T<#)@`$44!@1,#$JCIR+5<!A50[##L8?#%&A(HF.9(XP7G!PU^_\*4
M$N3MCX"ZBP(,JKL``8`L)#1(()/EQHL7.<R\T%-!18:ND%6%<7*E!`4)-6XL
MO'%F38X67DJX.(%`A(I8C_`>TGLH3XX<&8Q!D=$$1A4S9EK<\++'0Y,!D8-K
MRN!$A@(I94A@X'!C((8#+*`,H&$WD6I!<P_5K1O@P1\WWND^(,+ARYA"=1-`
M@%($3(L72VZ`4(`$`FKA^!<)R(#@@@0@/:!@P1$<Y"`!!09H\$AVA-1EQ1\/
ML%8=77BM(`AK`@00`PE5C,!(&'\D<$4$"I"10Q8HQ(!``OFU:`@$5$AAP0L<
M*'?8"U1H\)@A"Q`APH\_=D"7(`\4.22$$$HH2/\&&CA`72$2LJ%`#3!<QP@-
M3WB1Q0M32*&#$A%&J(8:#ZCA1@!H=J=FA&F&J6:;:[*)IIML@D?FG6["6>2;
M<ZZ9II]RQCFF&MW)2>>?="(B@!(*O``0!@-Q<`0!4`1AR`,.4)`&"3<`T4(/
MH/8PP1]A9#B(7FDB2>1>!!2H`J%_H!FK(`@XND,`JEWG'8.EJ'`"!0D!H<,`
M][G8504XH-##%#F@D$4-)DR0@G9!&$""&18<L(<//FRK``]-5,>@(1FZ*<@"
M$F`0PX4/@'=A"4!$H!V2X6UEI2`C;&$"!E,<H(%&QG+$Q`=5*)O#&@T`$44%
MEB+B1`0U8&``'PF,@D7_!EQD8(0#?[31AAM_K)"J(&ZL$)Z$`:A10`UIP.$N
MR(($T0()P)$[R`,"K+!5=>$50H,+G7)PQ[@!]](&'VE(2F,-)*0A`B$P$T)%
M#QAXL..J@VA45X2#A''F(@M$D07'AH30@`4S'%+*`R;CY5UX5F8@0Q3TG`!P
MT;Y044:!662Q5@D-$\+V!H0[T(,%'C38<:P8MH$SD>W6I4:&&XC,]@HP6^L!
M&R%?WL$-96B!2';>@.S="M[H=9<A&420G`M$XRT+`_-`FH-+2,1.5RD1'+'$
MDW:5,A=K<^6,1A(./(:Y71+ZX8`#:.";A10G%.+"%&;4W,$T1`@P`1X,"!$"
M_P!/0*!:$`"$$((*ARR@PQH2>"B[+7<XV^P+0(!!B(5NPOH'"$M8UVJX(P@U
M="`*4NC!"VIP`([M3`UAZT$-I@`$#VS@#S"H@0(@=*84^``%,&A#$O0`(""\
M0`(A:`@6B+`'T##@:W\P`0FB`#S%=2`''(#"_&RQ!2`(I"(Y,,"1#O&`!%@`
M!PP@1`H8(`<G,,`)<B`"%JP@@"3@@`-F`,$9&G`$'!#!+F[00`36D(46T$$,
M63@`$4)`@C6P3Q`#:`$'QC``S-0@!R`P`PK2<(\%"(`!:<#`'8P@B%:A0$&*
MT$$#JK=#6A3@)'JD`P80,*0X[,5"$'+"#0ZP`$+H0/\"/PAE*"7@@C^`XPM@
M&`,1',`'&)@!!QP3`@@L8`(^.``"`&@!`U7P`@Q<81`76,,-B!`%(.``"A!@
M``(H\(4>G*&3?]``<Q('A2G,80N)F`L"+$#)1M+""Q7!7PU&9:J0K<!DW[$0
M`TC`R4$X@1Y'N-T1+-"`'[1A#"^@0"&8H(`OX.`/18`(YP:A!,*XP``UD``3
M-B#+,]QA`B]0``WPDH$#H``#P+L"0ZB0+EAD,T)$29LW9\&'*AP.!7/PP2`>
MA`@&U.-I@DC`![!6`11,@081F`,?#`&%9@K`!"@@`'J@0`(8:,`+)'B:!NJ)
MA3R0H`+7V0$'^A`X`5```U__^`(&R*8(!I3!"2.E!1/X<(1KO48)>)$0UP21
MAAL(51!^T`BJ_H"`,DA!!#\X`XL$48`KC($*&+``$0Z0`T8R[@]$V&0;K"7$
M"UB`!7](@QCV2@@$-`6:=H'"`>Y1`$5X(P,QJ%E8:>&`?O8@!U'8J24AA,Z0
M"2(&/5C#%PLQEP%DX0<B`$$#GC2`!BP!6W.H`01PL`09*`X"+5C"'YR0!1QH
M``0OH"08SN`'0R``!5^@[!^0]0(47.%NAU"!#+0[VEFDX`0ZH%$/7+#00O0L
M`5*88>`*,8`I_(`!$4#!3NFZ!RKXEPHAX.<1BH"U-X2@#/H40`3L^P(?I`UB
M!;C._P1RT`#,=@`'-:A",\-UB!DH801O*"\M,B0A#W"@!R0P0"S<X(8V7#!)
M`K@`$#!``.YT)U8#>,$/!#"$'/"`5B%330F>(]),&H3#(4`!#D7WAR>(@89X
MF<$/4$`"X+G@)2=0@$VY2@@NZ$[$JGCO%F#P@BBX0`45NM`"M$!E"KB`#\E\
MHA/^\H,_="`-*%#`"9R0@#[WV8\T6`(&%,`')S@!"B`P)C07$$@4$#)$!^C!
M,0T]`!V<%@/0%`$&7@!9!Y!A"@K840(ZT`'P0B(%8$V%$QYMBP1@5A$/,I)W
MO-&&`8S!`S@@@!/NYK\"D`$%#1`#"`Y0DA_(H\[1C&T6)/\0!1Y$X=D\J,`?
M^!"%)7!``@<84!4064@2R&L0"*@"":X=Z2,<3@S0Y($%#`#-`8!`#%9!YD!+
MRR(XL,"XC(`"!>ZE"!%$`">F1@03NL#M1<0@<33PP`XR80,HI```2E#4=DY%
M6S8@P`,P((`#-J`:(UQ!!UZH1Q7(`((6?%I^-"``!?+X`RY-H04Z8(,`V.`"
M'DCA"!0(P4`'T0K1ZH4&)S!!"](`!@.,``922-\!JJ"`:0UB`$8U-1%:$&$\
M`$$]61$$!`:P"QK\"!VK[@`-!O"8%0Z@%!D8@`BN!@(`$.</"W"`"&*A#1'P
M&>[VF;L*&$`$-/^!`5DQWR"F0(7_/PR@!GR@02<7H((VC"`!`YC!`LX>(@1`
MX#%$\(-I<+P``)0!"BH@Y`R22*&>M79"A.B\B@;@`"M@\@\IJ```TC?[VLN!
M$!T(P0[&-_OQ41:7`$AU(8*P@QVIA@&S1^0(:K\#`,B/$0D``1(RH``#)``>
M'D@!`A2@!UVSP`1ZZ(`'V.&!#QQ`V@50@`)DD((KZ,$#LVV#!-@M@"!H00\Z
MJ,`#"$"`*'@`"7]@`![@!"R0`A?@`0H``S0P`B1"``J`!=[`!@U@`!`P!"A`
M!"[0616@!=<7`UTP`?[!,3N@`'D`!1F0!Q]@`Q&0`D'`&":0!39P`3IT`EJP
M':DC*Z.#_QXTX``,\$31,PG\!@D"L%:*H"18<PA!$`5:L'VC,``N4`8#D`90
M(`P*4`1*`!(YX`!;4`(.$`-%0`0@H`$B4`/N!@58<!]\<`,\,`)/``-S!@,C
MP`,?H`(JF``4L$81X`!1$`,C0#-5:`0?(`75(0(-$`5VL%D94`641`5-4`!'
M``5:T`(54`0[(``CH`$FX`,,T`/()`'&0`%&H`,4D``N0`5,<`0C8&,2,CQJ
M,BM?UC%!:`BOV`AWL3JQN!>T)AY#1`AM``,LH`-\0'U(8``W@%=.EP-H]0<3
M<`98X`4[U01W<`$'\!,7<0`\P"`BT`(&4`(10``?H'L@("10`/\#)5`]+/`!
M$S`%,R`$-:`$:T!),D!@@C`$$L`Q$6`"6)`#3M`&!U``_1<$'G`!06!4QH$`
MN58!"L`$*H`#">`!!.8%A;=,!""/I=<QX5$FBO!BEM`SA_!Z$@>+L<)BB^`&
M>%&+LW8()5`%\D(#55`!%,"0!U`"2,`H:;`#?*`%7C`#-P!6/'`"#O`%4%`!
M,X``&N`!9S!030``!'`&"#`&.J`!&A`$+*``G$-,)J`1!P`!!)`&?P``)!`&
M5@$`53`J@O"'?U`#!3`#9Z`%)2`%#L`#\I(&&B``$N`$75`"(5!86D!@(A`%
M*9`#(?`',+=W-Y`%\[4Z?T`F@[`S1$+_/&I0"AXI"741->[5.>=T3B7#D1=B
M.B0Y.G5!-*52""<0`=+&!%I@`*?)!`@9`2-`!!$0`0B@!4.0<I;"`D_S!#9`
M`%S`!Q[@`8S4!A-@!P0P`5B0`$40@]7"84%``./P!Q&P`!,@5!508P@@&CJ@
M0X)`!070!ECP)0$8`2$`."Q0/1Y``TQ@-1<7`@0P`$,@;4[H/F`U!!%`!!DP
M!Q&0*P)P)GJQ`ALP:P'`4D<H`+.X""#"BS>CF8:P`6I0!VA"F=AA);1V)FPS
MA+,6B][`;[>(BZ@W+^*2*[0E"&\F`S@@)#;C$>02.]XP`!=@`L]'(8NY4H/@
M."$Y)R`C`&I@H#)64"1LLZ,FHZ,FXY%B\J`]8X0-HAIH8B;N`IJK@Z`;2BZW
MF*&1,'&,```N,`9<P`FJPV\54$I.RI@-\I]0(PBOUP906@@MII$00J:$$`".
MLR:*>1>X$BN$@J38,2YJ>BG=@9C:<:&*4#R94&37@9AE2@E96@DXTZ.\:"25
E>0D<]Z4WY@B/XUX(.H1M4`<Q2H1!**B.,*!"F$VHH*>-$`@`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
